NEW YORK & AMSTERDAM--(BUSINESS WIRE)--Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, ...

Series A Financing led by EcoR1 Capital, Jeito Capital and Syncona with continued support of strategic seed investors Vida Ventures, TPG and Two River Neogene’s proprietary technology platform ...

Partnership Combines Twist’s Leadership in DNA Synthesis and Synthetic Biology with Neogene’s Expertise in Personalized Engineered T Cell Therapies “Engineered T cell therapies have demonstrated ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

A new neoantigen T-cell player has launched with Neogene Therapeutics nabbing a major $110 million series A. The funding haul, a significant sum for a first round, was led by by EcoR1 Capital, Jeito ...

With the acquisition of Neogene Therapeutics this week and a CAR-T now in phase 1 courtesy of a Chinese deal, AstraZeneca hopes to add the first volumes to a planned “library” of off-the-shelf cell ...

FILE PHOTO: A company logo is seen at the AstraZeneca site in Macclesfield (Reuters) -AstraZeneca will acquire biotechnology company Neogene Therapeutics for up to $320 million, the London-listed ...

Nov 29 (Reuters) - AstraZeneca AZN.L said on Tuesday it would acquire Neogene Therapeutics, a developer of cell-based cancer treatments, for up to $320 million, as the London-listed drugmaker seeks to ...

NEW YORK & AMSTERDAM--(BUSINESS WIRE)--Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, ...

Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced the appointment of ...